Icosavax — Technical Presentation (December 2022)
11 slides from Icosavax's technical presentation, Dec 13, 2022
Slide 1: IVX-121 Ph 1/1b Six-Month Durability Update
IVX-121 Ph 1/1b Six-Month Durability Update December 13, 2022 Exhibit 99.1
Slide 2: Forward looking statements
Forward looking statements Statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company’s current beliefs and expectations and include but are not limited to: the potential for the co
Slide 3: Positive IVX-121 Phase 1/1b Topline Interim Results and Six-Month Immunogenicity Update
Positive IVX-121 Phase 1/1b Topline Interim Results and Six-Month Immunogenicity Update As reported in June and December 2022, respectively Initial indication of the company’s differentiated VLP platform technology High RSV-A and RSV-B neutralizing antibody titers seen from the lowest dose tested Po
Slide 4: Topline immunogenicity data: RSV-A nAb (unadjuvanted); updated GMT expressed in IU/mL
Topline immunogenicity data: RSV-A nAb (unadjuvanted); updated through day 180 GMT expressed in IU/mL GMTs for RSV-A at day 180 were maintained within a range of 64-98% relative to the previously reported GMTs at day 28 GMT: Geometric mean titer; LLoQ = 9.9; GMFR: Geometric Mean Fold Rise (Day 28) f
Slide 5: IVX-121 elicits high and durable RSV-A nAb titers relative to NIH DS-Cav1 antigen
At comparable or lower antigen dose equivalents, IVX-121 elicits high and durable RSV-A nAb titers relative to those previously shown by NIH for DS-Cav1 antigen; updated through day 180 DS-Cav1 soluble protein Ph 1 (NIH)3 YA immunogenicity, day 28 – day 180 post dose (unadjuvanted): RSV-A neutraliza
Slide 6: Neutralizing antibody titers in older adults for IVX-121 and a leading RSV vaccine candidate
120 µg dose recently demonstrated ~85% overall efficacy in a Ph 3 efficacy OA study4 Neutralizing antibody titers through day 180 in older adults for IVX-121 and a leading RSV vaccine candidate RSVpreF soluble protein (Pfizer; estimated titers) IVX-121 VLP (Older Adults)2 **Data shown side by side f
Slide 7: Continued favorable IVX-121 tolerability data in Phase 1/1b study
Continued favorable IVX-121 tolerability data in Phase 1/1b study RSV vaccines – OA Shingles vaccine Quadrivalent influenza vaccines – OA1 RSVpreF RSVpreF3 (w/ AS01E adj.) Ad26.RSV. preF + preF mRNA-13452 Shingrix (w/ AS01B adj.) Fluzone Flublok Fluad (w / MF59 adj.) mRNA-10103 IVX-1216 OA: 25-250 µ
Slide 8: Appendix
Os) ICOSAVAX Appendix
Slide 9: IVX-121 for RSV: Ph 1/1b study design and timeline
IVX-121 for RSV: Ph 1/1b topline interim data was presented in June 2022, with six-month immunogenicity update provided in December 2022 Phase 1b EXTENSION Subset of Ph 1b OA cohort Up to 12 months follow-up Revaccination at 12 months after initial Ph 1b dose Following the Phase 1/1b topline data, w
Slide 10: IVX-121 GMT ranges for RSV-A and RSV-B in older adults
IVX-121 GMT ranges for RSV-A and RSV-B in older adults GMTs for RSV-B showed greater variability but were maintained above baseline through day 180 Day 28 Day 180 GMT (95% CI) IVX-121 Day 28 and Day 180 Results (Unadjuvanted) Older Adult Subjects (ages 60-75) PH1b 25 µg 75 µg 250 µg PBO RSV-A GMT (9
Slide 11: Older Adult RSV and/or hMPV Pipeline Candidates
VLP Recombinant Vector Janssen* Adenovirus + soluble RSV-F Bavarian Nordic MVA RSV-F Most technologically competitive w/ Icosavax Nucleic Acid Moderna RSV-F Sanofi: RSV Sanofi: RSV + hMPV RSV-F + hMPV RSV-F Protein / Subunit / Soluble Antigen GSK RSV-F + AS01 Pfizer RSV-F ViceBio: RSV Moderna: RSV +